Figure 6.
The effect of recombinant IL17A on body weight, liver weight and glucose tolerance in NASH mice. (A) In a 15 day pharmacological study, change in body weight was monitored every day. NASH mice were injected i.p. with 3.7 mg·kg−1 PsTag600‐FGF21 every 3 days and 25 μg·kg−1 rIL17A twice a day. (B) Liver weight/body weight (%) of mice after 15 days of treatment. (C) For OGTT, blood glucose and the glucose AUC from 0 to 120 min were measured. Data shown are means ± SD (n = 10 per group). *P < 0.05, significantly different from vehicle‐treated NASH mice; # P < 0.05, significantly different from PsTag600‐FGF21‐treated NASH mice.